Loading…

Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study

Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI). Method: This was a prospective randomized study conducted at Kocael...

Full description

Saved in:
Bibliographic Details
Published in:Bagcilar Medical Bulletin 2022-03, Vol.7 (1), p.63-69
Main Authors: Aynıoğlu, Öner, Ceylan, Yasin, Akar, Bertan, Özdemir Özkan, Sebiha, Çalışkan, Eray, Doğer, Emek, Çakıroğlu, Yiğit
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2017-c8a714dee61a71cda4c802d920fdaf93b6d81f717e953445c761e4c705acc9613
container_end_page 69
container_issue 1
container_start_page 63
container_title Bagcilar Medical Bulletin
container_volume 7
creator Aynıoğlu, Öner
Ceylan, Yasin
Akar, Bertan
Özdemir Özkan, Sebiha
Çalışkan, Eray
Doğer, Emek
Çakıroğlu, Yiğit
description Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI). Method: This was a prospective randomized study conducted at Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, in vitro fertizilization (IVF) Unit. A total of 91 PCOS patients undergoing ICSI were randomly assigned to receive either r-FSH (n=46) or HPuFSH (n=45) with a gonadotropin releasing hormone (GnRH) antagonist protocol. The main outcome measures were the number of mature oocytes retrieved, embryo quality, pregnancy rates, implantation rates. Results: The number of mature oocytes retrieved, fertilization rates, the number of cryopreserved embryos were significantly higher in r-FSH group (p=0.024, p=0.023, p=0.026 respectively) while the total dose of FSH used was significantly lower in the same group (p=0.023). Pregnancy rates, clinical pregnancy rates were higher in r-FSH group although not statistically significant (52.2% versus 35.6%, p=0.11, 37% versus 28.9%, p=0.41 respectively). Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups. Conclusion: r-FSH is superior than HP-uFSH in PCOS regarding fertilization rates, the number of mature oocytes retrieved and cryopreserved embryos, pregnancy rates although overall therapy costs per clinical pregnancy are higher.
doi_str_mv 10.4274/BMB.galenos.2022.2021-05-057
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_23659af0074e415a893d837137969f1f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_23659af0074e415a893d837137969f1f</doaj_id><sourcerecordid>2833994793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2017-c8a714dee61a71cda4c802d920fdaf93b6d81f717e953445c761e4c705acc9613</originalsourceid><addsrcrecordid>eNpNkW9r2zAQxs3YYKXtdxBsb53pny1r7E0b1iXQ0dAseytU6ewqOFIm2R3e59gHrtyUMTjujuPHc3c8RfGR4AWngn-6_n696HQPPqQFxZTOiZS4yiHeFGe04qKUnJG3__Xvi8uU9hhj2lR1Q-uz4u89mHB4cF77Ad1sV-gnxDQmtHLdYz-hzRhd68CiXcxInF4Q59FGDw78kNBvNzyiTegnM6XBGXT3NFPbydsYDoB23kLsgvMdWi-3a7ScTA_pM7pCmxjSEczgngDda2_Dwf3Je7bDaKeL4l2r-wSXr_W82N18_bFclbd339bLq9vSUExEaRotCLcANcmNsZqbBlMrKW6tbiV7qG1DWkEEyIpxXhlRE-BG4EobI2vCzov1SdcGvVfH6A75eBW0Uy-DEDulY_6qB0VZXUndYiw4cFLpRjLbMEGYkLVsSZu1Ppy0jjH8GiENah_G6PP5ijaMScmFZJn6cqJMfj9FaP9tJVjNtqpsq3q1Vc22zokoXOUQ7Bmad5kM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2833994793</pqid></control><display><type>article</type><title>Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study</title><source>Publicly Available Content (ProQuest)</source><creator>Aynıoğlu, Öner ; Ceylan, Yasin ; Akar, Bertan ; Özdemir Özkan, Sebiha ; Çalışkan, Eray ; Doğer, Emek ; Çakıroğlu, Yiğit</creator><creatorcontrib>Aynıoğlu, Öner ; Ceylan, Yasin ; Akar, Bertan ; Özdemir Özkan, Sebiha ; Çalışkan, Eray ; Doğer, Emek ; Çakıroğlu, Yiğit</creatorcontrib><description>Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI). Method: This was a prospective randomized study conducted at Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, in vitro fertizilization (IVF) Unit. A total of 91 PCOS patients undergoing ICSI were randomly assigned to receive either r-FSH (n=46) or HPuFSH (n=45) with a gonadotropin releasing hormone (GnRH) antagonist protocol. The main outcome measures were the number of mature oocytes retrieved, embryo quality, pregnancy rates, implantation rates. Results: The number of mature oocytes retrieved, fertilization rates, the number of cryopreserved embryos were significantly higher in r-FSH group (p=0.024, p=0.023, p=0.026 respectively) while the total dose of FSH used was significantly lower in the same group (p=0.023). Pregnancy rates, clinical pregnancy rates were higher in r-FSH group although not statistically significant (52.2% versus 35.6%, p=0.11, 37% versus 28.9%, p=0.41 respectively). Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups. Conclusion: r-FSH is superior than HP-uFSH in PCOS regarding fertilization rates, the number of mature oocytes retrieved and cryopreserved embryos, pregnancy rates although overall therapy costs per clinical pregnancy are higher.</description><identifier>ISSN: 2547-9431</identifier><identifier>EISSN: 2547-9431</identifier><identifier>DOI: 10.4274/BMB.galenos.2022.2021-05-057</identifier><language>eng</language><publisher>Bagcilar: Galenos Publishing House</publisher><subject>Androgens ; Body mass index ; Embryology ; Embryos ; Endometriosis ; hp-ufsh ; Infertility ; Metabolism ; Ovaries ; Ovulation ; Patients ; pcos ; Polycystic ovary syndrome ; Pregnancy ; rec-fsh ; Ultrasonic imaging ; Urine</subject><ispartof>Bagcilar Medical Bulletin, 2022-03, Vol.7 (1), p.63-69</ispartof><rights>2022. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2017-c8a714dee61a71cda4c802d920fdaf93b6d81f717e953445c761e4c705acc9613</cites><orcidid>0000-0002-6799-5909 ; 0000-0002-2779-8599 ; 0000-0003-2959-0350 ; 0000-0002-8941-5469 ; 0000-0003-0494-6867 ; 0000-0001-5517-8461 ; 0000-0003-2283-5618</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2833994793/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2833994793?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25732,27903,27904,36991,44569,74872</link.rule.ids></links><search><creatorcontrib>Aynıoğlu, Öner</creatorcontrib><creatorcontrib>Ceylan, Yasin</creatorcontrib><creatorcontrib>Akar, Bertan</creatorcontrib><creatorcontrib>Özdemir Özkan, Sebiha</creatorcontrib><creatorcontrib>Çalışkan, Eray</creatorcontrib><creatorcontrib>Doğer, Emek</creatorcontrib><creatorcontrib>Çakıroğlu, Yiğit</creatorcontrib><title>Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study</title><title>Bagcilar Medical Bulletin</title><description>Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI). Method: This was a prospective randomized study conducted at Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, in vitro fertizilization (IVF) Unit. A total of 91 PCOS patients undergoing ICSI were randomly assigned to receive either r-FSH (n=46) or HPuFSH (n=45) with a gonadotropin releasing hormone (GnRH) antagonist protocol. The main outcome measures were the number of mature oocytes retrieved, embryo quality, pregnancy rates, implantation rates. Results: The number of mature oocytes retrieved, fertilization rates, the number of cryopreserved embryos were significantly higher in r-FSH group (p=0.024, p=0.023, p=0.026 respectively) while the total dose of FSH used was significantly lower in the same group (p=0.023). Pregnancy rates, clinical pregnancy rates were higher in r-FSH group although not statistically significant (52.2% versus 35.6%, p=0.11, 37% versus 28.9%, p=0.41 respectively). Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups. Conclusion: r-FSH is superior than HP-uFSH in PCOS regarding fertilization rates, the number of mature oocytes retrieved and cryopreserved embryos, pregnancy rates although overall therapy costs per clinical pregnancy are higher.</description><subject>Androgens</subject><subject>Body mass index</subject><subject>Embryology</subject><subject>Embryos</subject><subject>Endometriosis</subject><subject>hp-ufsh</subject><subject>Infertility</subject><subject>Metabolism</subject><subject>Ovaries</subject><subject>Ovulation</subject><subject>Patients</subject><subject>pcos</subject><subject>Polycystic ovary syndrome</subject><subject>Pregnancy</subject><subject>rec-fsh</subject><subject>Ultrasonic imaging</subject><subject>Urine</subject><issn>2547-9431</issn><issn>2547-9431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpNkW9r2zAQxs3YYKXtdxBsb53pny1r7E0b1iXQ0dAseytU6ewqOFIm2R3e59gHrtyUMTjujuPHc3c8RfGR4AWngn-6_n696HQPPqQFxZTOiZS4yiHeFGe04qKUnJG3__Xvi8uU9hhj2lR1Q-uz4u89mHB4cF77Ad1sV-gnxDQmtHLdYz-hzRhd68CiXcxInF4Q59FGDw78kNBvNzyiTegnM6XBGXT3NFPbydsYDoB23kLsgvMdWi-3a7ScTA_pM7pCmxjSEczgngDda2_Dwf3Je7bDaKeL4l2r-wSXr_W82N18_bFclbd339bLq9vSUExEaRotCLcANcmNsZqbBlMrKW6tbiV7qG1DWkEEyIpxXhlRE-BG4EobI2vCzov1SdcGvVfH6A75eBW0Uy-DEDulY_6qB0VZXUndYiw4cFLpRjLbMEGYkLVsSZu1Ppy0jjH8GiENah_G6PP5ijaMScmFZJn6cqJMfj9FaP9tJVjNtqpsq3q1Vc22zokoXOUQ7Bmad5kM</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Aynıoğlu, Öner</creator><creator>Ceylan, Yasin</creator><creator>Akar, Bertan</creator><creator>Özdemir Özkan, Sebiha</creator><creator>Çalışkan, Eray</creator><creator>Doğer, Emek</creator><creator>Çakıroğlu, Yiğit</creator><general>Galenos Publishing House</general><general>Galenos Yayinevi</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6799-5909</orcidid><orcidid>https://orcid.org/0000-0002-2779-8599</orcidid><orcidid>https://orcid.org/0000-0003-2959-0350</orcidid><orcidid>https://orcid.org/0000-0002-8941-5469</orcidid><orcidid>https://orcid.org/0000-0003-0494-6867</orcidid><orcidid>https://orcid.org/0000-0001-5517-8461</orcidid><orcidid>https://orcid.org/0000-0003-2283-5618</orcidid></search><sort><creationdate>20220301</creationdate><title>Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study</title><author>Aynıoğlu, Öner ; Ceylan, Yasin ; Akar, Bertan ; Özdemir Özkan, Sebiha ; Çalışkan, Eray ; Doğer, Emek ; Çakıroğlu, Yiğit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2017-c8a714dee61a71cda4c802d920fdaf93b6d81f717e953445c761e4c705acc9613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Androgens</topic><topic>Body mass index</topic><topic>Embryology</topic><topic>Embryos</topic><topic>Endometriosis</topic><topic>hp-ufsh</topic><topic>Infertility</topic><topic>Metabolism</topic><topic>Ovaries</topic><topic>Ovulation</topic><topic>Patients</topic><topic>pcos</topic><topic>Polycystic ovary syndrome</topic><topic>Pregnancy</topic><topic>rec-fsh</topic><topic>Ultrasonic imaging</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aynıoğlu, Öner</creatorcontrib><creatorcontrib>Ceylan, Yasin</creatorcontrib><creatorcontrib>Akar, Bertan</creatorcontrib><creatorcontrib>Özdemir Özkan, Sebiha</creatorcontrib><creatorcontrib>Çalışkan, Eray</creatorcontrib><creatorcontrib>Doğer, Emek</creatorcontrib><creatorcontrib>Çakıroğlu, Yiğit</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Bagcilar Medical Bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aynıoğlu, Öner</au><au>Ceylan, Yasin</au><au>Akar, Bertan</au><au>Özdemir Özkan, Sebiha</au><au>Çalışkan, Eray</au><au>Doğer, Emek</au><au>Çakıroğlu, Yiğit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study</atitle><jtitle>Bagcilar Medical Bulletin</jtitle><date>2022-03-01</date><risdate>2022</risdate><volume>7</volume><issue>1</issue><spage>63</spage><epage>69</epage><pages>63-69</pages><issn>2547-9431</issn><eissn>2547-9431</eissn><abstract>Objective: To compare efficacy and safety of recombinant follicule stimulating hormone (r-FSH) and highly purified urinary FSH (HPuFSH) in polycystic ovary syndrome (PCOS) patients undergoing intracytoplasmic sperm injection (ICSI). Method: This was a prospective randomized study conducted at Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, in vitro fertizilization (IVF) Unit. A total of 91 PCOS patients undergoing ICSI were randomly assigned to receive either r-FSH (n=46) or HPuFSH (n=45) with a gonadotropin releasing hormone (GnRH) antagonist protocol. The main outcome measures were the number of mature oocytes retrieved, embryo quality, pregnancy rates, implantation rates. Results: The number of mature oocytes retrieved, fertilization rates, the number of cryopreserved embryos were significantly higher in r-FSH group (p=0.024, p=0.023, p=0.026 respectively) while the total dose of FSH used was significantly lower in the same group (p=0.023). Pregnancy rates, clinical pregnancy rates were higher in r-FSH group although not statistically significant (52.2% versus 35.6%, p=0.11, 37% versus 28.9%, p=0.41 respectively). Overall therapy costs per clinical pregnancy were associated with a 9.94% increase in r-FSH group whereas costs per pregnancy were not different between groups. Conclusion: r-FSH is superior than HP-uFSH in PCOS regarding fertilization rates, the number of mature oocytes retrieved and cryopreserved embryos, pregnancy rates although overall therapy costs per clinical pregnancy are higher.</abstract><cop>Bagcilar</cop><pub>Galenos Publishing House</pub><doi>10.4274/BMB.galenos.2022.2021-05-057</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6799-5909</orcidid><orcidid>https://orcid.org/0000-0002-2779-8599</orcidid><orcidid>https://orcid.org/0000-0003-2959-0350</orcidid><orcidid>https://orcid.org/0000-0002-8941-5469</orcidid><orcidid>https://orcid.org/0000-0003-0494-6867</orcidid><orcidid>https://orcid.org/0000-0001-5517-8461</orcidid><orcidid>https://orcid.org/0000-0003-2283-5618</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2547-9431
ispartof Bagcilar Medical Bulletin, 2022-03, Vol.7 (1), p.63-69
issn 2547-9431
2547-9431
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_23659af0074e415a893d837137969f1f
source Publicly Available Content (ProQuest)
subjects Androgens
Body mass index
Embryology
Embryos
Endometriosis
hp-ufsh
Infertility
Metabolism
Ovaries
Ovulation
Patients
pcos
Polycystic ovary syndrome
Pregnancy
rec-fsh
Ultrasonic imaging
Urine
title Recombinant FSH Versus Highly Purified Urinary FSH in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Prospective Randomized Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A29%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20FSH%20Versus%20Highly%20Purified%20Urinary%20FSH%20in%20Patients%20with%20Polycystic%20Ovary%20Syndrome%20Undergoing%20ICSI%20Cycles:%20A%20Prospective%20Randomized%20Study&rft.jtitle=Bagcilar%20Medical%20Bulletin&rft.au=Ayn%C4%B1o%C4%9Flu,%20%C3%96ner&rft.date=2022-03-01&rft.volume=7&rft.issue=1&rft.spage=63&rft.epage=69&rft.pages=63-69&rft.issn=2547-9431&rft.eissn=2547-9431&rft_id=info:doi/10.4274/BMB.galenos.2022.2021-05-057&rft_dat=%3Cproquest_doaj_%3E2833994793%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2017-c8a714dee61a71cda4c802d920fdaf93b6d81f717e953445c761e4c705acc9613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2833994793&rft_id=info:pmid/&rfr_iscdi=true